Clinical Trials in Xian, Shanxi
32 recruiting
Showing 1–20 of 29 trials
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled492 locationsNCT07517263
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled216 locationsNCT06345729
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled157 locationsNCT07011732
Recruiting
Phase 2Phase 3
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Prostate Cancer
Novartis Pharmaceuticals443 enrolled72 locationsNCT06780670
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 1Phase 2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled92 locationsNCT06813911
Recruiting
Phase 2
JS207 Combination Therapy in Triple-negative Breast Cancer
Triple-Negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.80 enrolled22 locationsNCT07045311
Recruiting
Phase 4
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
Plaque, Atherosclerotic
Novartis Pharmaceuticals334 enrolled20 locationsNCT06372925
Recruiting
Phase 1
A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Nanjing Leads Biolabs Co.,Ltd112 enrolled11 locationsNCT07323173
Recruiting
Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
Advanced Liver Cancer
Abbisko Therapeutics Co, Ltd200 enrolled32 locationsNCT04906434
Recruiting
Phase 2
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
Ulcerative Colitis
InSilico Medicine Hong Kong Limited80 enrolled28 locationsNCT07265570
Recruiting
Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
NeoplasmsTenosynovial Giant Cell Tumor
Abbisko Therapeutics Co, Ltd276 enrolled17 locationsNCT04192344
Recruiting
Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Lupus Nephritis
Novartis Pharmaceuticals462 enrolled188 locationsNCT05126277
Recruiting
Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Hidradenitis Suppurativa
Novartis Pharmaceuticals555 enrolled145 locationsNCT06799000
Recruiting
Phase 4
Asciminib Roll-over Study
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals347 enrolled84 locationsNCT04877522
Recruiting
Phase 3
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Nasopharyngeal Carcinoma
Sun Yat-sen University593 enrolled26 locationsNCT06239727
Recruiting
Phase 4
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
Steroid-refractory Acute Graft Versus Host Disease
Novartis Pharmaceuticals36 enrolled17 locationsNCT06462469
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686